3/31
04:05 pm
ttrx
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Low
Report
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
3/30
09:02 am
ttrx
Turn Therapeutics Secures $25M Financing for Dermatology Trials [Los Angeles Times (CA)]
Low
Report
Turn Therapeutics Secures $25M Financing for Dermatology Trials [Los Angeles Times (CA)]
3/24
03:02 pm
ttrx
Turn Therapeutics (TTRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $8.00 price target on the stock.
Medium
Report
Turn Therapeutics (TTRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $8.00 price target on the stock.
3/24
08:00 am
ttrx
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Low
Report
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
2/17
08:00 am
ttrx
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
High
Report
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
2/9
08:42 am
ttrx
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences [Yahoo! Finance]
Low
Report
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences [Yahoo! Finance]
2/9
08:00 am
ttrx
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Low
Report
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
1/20
08:02 am
ttrx
Turn Therapeutics (NASDAQ:TTRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $8.00 price target on the stock.
Low
Report
Turn Therapeutics (NASDAQ:TTRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $8.00 price target on the stock.